Skip to main content

Table 1 The detailed information of AS patients

From: IgG Galactosylation status combined with MYOM2-rs2294066 precisely predicts anti-TNF response in ankylosing spondylitis

Parameter

Baseline (Mean ± SD, N = 79)

Week 2 (Mean ± SD, N = 79)

Week 4(Mean ± SD, N = 79)

Week 8 (Mean ± SD, N = 79)

Week 12 (Mean ± SD. N = 79)

Male n (%)

70 (89)

age

36.0 ± 11.5

HLA-B27 (%)

98.7

disease duration (months)

7.3 ± 8.0

NSAIDS (%)

82.3

Psoriasis (%)

0

Rheumatoid Arthritis (%)

0

Inflammatory Bowel Disease

0

BASDAI

5.4 ± 1.0

3.4 ± 1.5

2.2 ± 1.1

1.7 ± 1.0

1.4 ± 0.8

BASFI

3.2 ± 2.2

2.1 ± 1.8

1.4 ± 1.5

1.1 ± 1.2

0.9 ± 1.1

CRP

20.8 ± 32.2

3.8 ± 9.9

3.7 ± 10.0

3.1 ± 4.9

3.1 ± 4.2

ESR

28.3 ± 31.1

11.4 ± 19.7

8.4 ± 13.1

6.3 ± 6.8

6.5 ± 7.1

ASDAS

3.4 ± 0.8

1.8 ± 0.7

1.5 ± 0.7

1.2 ± 0.6

1.1 ± 0.7

  1. SD Standard deviation, BASDAI Bath Ankylosing Spondylitis Di, BASFI Bath Ankylosing Spondylitis Fu, ESR Erythrocyte sedimentation rate, CRP C reactive protein, ASDAS Ankylosing Spondylitis Disease NSADIS Non-steroidal anti-inflammator